Pegylated-Interferon - Globe Thesis

Keyword [Pegylated-Interferon] Result: 41 - 60 \| Page: 3 of 4
41.	Efficacy Of Sequential Pegylated Interferon Alpha-2a Treatments In Patients With Nucleoside-treated Chronic Hepatitis B And Its Early Prediction Of HBsAg Loss
42.	Relationship Between TCM Syndrome Types Of HBeAg Negative CHB And Biological Index And The Effect On The Efficacy Of Pegylated Interferon Alpha-2a
43.	Curative Effect And Long-Term Follow-Up Of Genotype 1 Patients With HCV-Related Compensated Cirrhosis Treated With PR And The Relationship Between Serum IL-35,IL-17 And Disease Progression Of Hepatitis C
44.	Optimized Treatment Of HBeAg Negative Chronic Hepatitis B And Necroptosis In Liver Failure
45.	An Efficient Study On HBsAg Clearance In Inactive HBsAg Carriers Treated With Pegylated Interferon Alpha-2b
46.	Combination Treatment Of Regimens Based On Peg-interferon Fou HBe Antigen Negative Chronic Hepatitis B Focusing On Hepatitis B Suiface Antigen Clearance Or Seroconversion:A Meta-analysis
47.	Analysis Of Factors Related To The Efficacy Of Pegylated Interferon In The Treatment Of Chronic Hepatitis B
48.	Efficacy Analysis Of Pegylated Interferon In Patients With Low-level HbsAg Chronic Hepatitis B Based On Real-world
49.	The meaning of adherence among veterans receiving pegylated interferon and ribavirin antiviral treatment for chronic hepatitis C
50.	Correlation Study Of CYP27B1-1260 Polymorphism And In-terferon Monotherapy/combination Therapeutic Response To Chronic Hepatitis B
51.	The Analysis Of Vitamin D Influencing The Outcomes Of Antiviral Therapy And The Prognosis In Patients With Chronic Hepatitis C
52.	The Predictive Value And Mechanism Of Hepcidin On The Antiviral Effect Of Pegylated-interferon-α In The Treatment Of Chronic Hepatitis B
53.	Analysis Of The Clinical Efficacy Of Sequential Combined Peg-IFN Treatment After NAs Treatment In CHB Patients
54.	Low Surface Antigen Patients With Chronic Hepatitis B Treated With Nucleoside Analogues(NAs) Combined With Pegylated Interferon α-2b Functional Therapy
55.	Analysis Of Related Factors Of HBsAg Decline Rate During The Treatment Of HBeAg-negative Chronic Hepatitis B With Pegylated Interferon-α-2b
56.	Clinical Study Of HbsAg Low-level Nucleoside (acid)analogues Treatment Of Chronic Hepatitis B Patients Combined With Long-acting Interferon Therapy
57.	A Clinical-Effectiveness Study Of Add-On Pegylated Interferon Alfa Therapy In Nucleos(t)ide Analogues Treated HBeAg Negative Chronic Hepatitis B Patients
58.	HBsAg Outcome Of Pegylated Interferon-α In The Treatment Of Chronic Hepatitis B
59.	Efficacy Of 48-week Sequential Therapy With Telbivudine Or Entecavir In HBeAg-positive Chronic Hepatitis B Patients With Suboptimal Responses To 24-week Therapy With Pegylated Interferon-α-2b
60.	Clinical Efficacy Analysis And Prediction Of Pegylated Interferon In Nucleoside Analogue Experienced Negative HBeAg Chronic Hepatitis B
<<First <Prev Next> Last>> Jump to